Press Release<< Back
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019
LIVE access on
4:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time
- Telephone 800-347-6311 (domestic) or 323-994-2131 (international); conference ID 3056397
- Webcast available at http://public.viavid.com/index.php?id=133623
- Telephone replay will be available for 30 days beginning at
7:30 p.m. ETon Thursday, March 28by calling 844-512-2921 (domestic) or 412-317-6671 (international); conference ID 3056397
- Webcast replay will be available on the
Achaogenwebsite at www.achaogen.com and will be archived for 30 days following the presentation
Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram negative infections. Achaogen’s first commercial product is ZEMDRI, for the treatment of adults with complicated urinary tract infections, including pyelonephritis. The Achaogen ZEMDRI program was funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). The Company is currently developing C-Scape, an orally administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA. C-Scape is investigational, has not been determined to be safe or efficacious, and has not been approved for commercialization. For more information, visit the
© 2019 Achaogen, Inc. All Rights Reserved.
Media and Investor Contact
Denise T. Powell Red House Consulting, LLCdenise@redhousecomms.com
Source: Achaogen, Inc.